Although their downregulation could be simply a bystander event during pancreatic cancer development, our findings revealed that the upregulations of ATF4, TXNIP, and REDD1 were concomitant with the therapeutic benefits of GW3965. Here, DDIT4 is linked to pancreatic neoplasm.